Constipation in Parkinson's Disease

Fabrizio Stocchi, Margherita Torti

Research output: Chapter in Book/Report/Conference proceedingChapter

12 Citations (Scopus)

Abstract

Constipation is one of the main and disabling nonmotor symptoms in Parkinson's disease (PD), with a prevalence ranging from 24.6% to 63% according to the different diagnostic criteria used to define chronic constipation. Constipation is currently recognized as a risk factor of PD in relation to the number of evacuation per week and its severity. Moreover, several studies have demonstrated that constipation may precede the occurrence of motor symptoms underlying an earlier involvement of the enteric nervous system and the dorsal motor nucleus of the vagus in the α-synuclein pathology. In PD, constipation is mainly due to slower colonic transit or puborectalis dyssynergia, but the concomitant use of antiparkinsonian, pain, and antidepressant medications may worsen it. An accurate diagnosis and an adequate treatment of constipation it is pivotal to prevent complications such as intestinal occlusion and to ensure an optimal clinical response to levodopa.

Original languageEnglish
Title of host publicationInternational Review of Neurobiology
PublisherAcademic Press Inc.
Pages811-826
Number of pages16
Volume134
DOIs
Publication statusPublished - Jan 1 2017

Publication series

NameInternational Review of Neurobiology
Volume134
ISSN (Print)0074-7742
ISSN (Electronic)2162-5514

Fingerprint

Constipation
Parkinson Disease
Synucleins
Antiparkinson Agents
Enteric Nervous System
Levodopa
Ataxia
Antidepressive Agents
Pathology
Pain

Keywords

  • Constipation
  • Enteric nervous system
  • Nonmotor symptoms
  • Parkinson's disease
  • PD risk factors
  • Puborectalis dyssynergia

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Stocchi, F., & Torti, M. (2017). Constipation in Parkinson's Disease. In International Review of Neurobiology (Vol. 134, pp. 811-826). (International Review of Neurobiology; Vol. 134). Academic Press Inc.. https://doi.org/10.1016/bs.irn.2017.06.003

Constipation in Parkinson's Disease. / Stocchi, Fabrizio; Torti, Margherita.

International Review of Neurobiology. Vol. 134 Academic Press Inc., 2017. p. 811-826 (International Review of Neurobiology; Vol. 134).

Research output: Chapter in Book/Report/Conference proceedingChapter

Stocchi, F & Torti, M 2017, Constipation in Parkinson's Disease. in International Review of Neurobiology. vol. 134, International Review of Neurobiology, vol. 134, Academic Press Inc., pp. 811-826. https://doi.org/10.1016/bs.irn.2017.06.003
Stocchi F, Torti M. Constipation in Parkinson's Disease. In International Review of Neurobiology. Vol. 134. Academic Press Inc. 2017. p. 811-826. (International Review of Neurobiology). https://doi.org/10.1016/bs.irn.2017.06.003
Stocchi, Fabrizio ; Torti, Margherita. / Constipation in Parkinson's Disease. International Review of Neurobiology. Vol. 134 Academic Press Inc., 2017. pp. 811-826 (International Review of Neurobiology).
@inbook{7778595170af424c86ffdcdbfeb499ee,
title = "Constipation in Parkinson's Disease",
abstract = "Constipation is one of the main and disabling nonmotor symptoms in Parkinson's disease (PD), with a prevalence ranging from 24.6{\%} to 63{\%} according to the different diagnostic criteria used to define chronic constipation. Constipation is currently recognized as a risk factor of PD in relation to the number of evacuation per week and its severity. Moreover, several studies have demonstrated that constipation may precede the occurrence of motor symptoms underlying an earlier involvement of the enteric nervous system and the dorsal motor nucleus of the vagus in the α-synuclein pathology. In PD, constipation is mainly due to slower colonic transit or puborectalis dyssynergia, but the concomitant use of antiparkinsonian, pain, and antidepressant medications may worsen it. An accurate diagnosis and an adequate treatment of constipation it is pivotal to prevent complications such as intestinal occlusion and to ensure an optimal clinical response to levodopa.",
keywords = "Constipation, Enteric nervous system, Nonmotor symptoms, Parkinson's disease, PD risk factors, Puborectalis dyssynergia",
author = "Fabrizio Stocchi and Margherita Torti",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/bs.irn.2017.06.003",
language = "English",
volume = "134",
series = "International Review of Neurobiology",
publisher = "Academic Press Inc.",
pages = "811--826",
booktitle = "International Review of Neurobiology",
address = "United States",

}

TY - CHAP

T1 - Constipation in Parkinson's Disease

AU - Stocchi, Fabrizio

AU - Torti, Margherita

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Constipation is one of the main and disabling nonmotor symptoms in Parkinson's disease (PD), with a prevalence ranging from 24.6% to 63% according to the different diagnostic criteria used to define chronic constipation. Constipation is currently recognized as a risk factor of PD in relation to the number of evacuation per week and its severity. Moreover, several studies have demonstrated that constipation may precede the occurrence of motor symptoms underlying an earlier involvement of the enteric nervous system and the dorsal motor nucleus of the vagus in the α-synuclein pathology. In PD, constipation is mainly due to slower colonic transit or puborectalis dyssynergia, but the concomitant use of antiparkinsonian, pain, and antidepressant medications may worsen it. An accurate diagnosis and an adequate treatment of constipation it is pivotal to prevent complications such as intestinal occlusion and to ensure an optimal clinical response to levodopa.

AB - Constipation is one of the main and disabling nonmotor symptoms in Parkinson's disease (PD), with a prevalence ranging from 24.6% to 63% according to the different diagnostic criteria used to define chronic constipation. Constipation is currently recognized as a risk factor of PD in relation to the number of evacuation per week and its severity. Moreover, several studies have demonstrated that constipation may precede the occurrence of motor symptoms underlying an earlier involvement of the enteric nervous system and the dorsal motor nucleus of the vagus in the α-synuclein pathology. In PD, constipation is mainly due to slower colonic transit or puborectalis dyssynergia, but the concomitant use of antiparkinsonian, pain, and antidepressant medications may worsen it. An accurate diagnosis and an adequate treatment of constipation it is pivotal to prevent complications such as intestinal occlusion and to ensure an optimal clinical response to levodopa.

KW - Constipation

KW - Enteric nervous system

KW - Nonmotor symptoms

KW - Parkinson's disease

KW - PD risk factors

KW - Puborectalis dyssynergia

UR - http://www.scopus.com/inward/record.url?scp=85023601049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023601049&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2017.06.003

DO - 10.1016/bs.irn.2017.06.003

M3 - Chapter

AN - SCOPUS:85023601049

VL - 134

T3 - International Review of Neurobiology

SP - 811

EP - 826

BT - International Review of Neurobiology

PB - Academic Press Inc.

ER -